Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 37

1.

HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas.

Sosin AM, Burger AM, Siddiqi A, Abrams J, Mohammad RM, Al-Katib AM.

J Hematol Oncol. 2012 Sep 18;5:57. doi: 10.1186/1756-8722-5-57.

PMID:
22989009
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Syncytial giant cell hepatitis associated with chronic lymphocytic leukemia: a case report.

Gupta E, Yacoub M, Higgins M, Al-Katib AM.

BMC Blood Disord. 2012 Jul 19;12:8. doi: 10.1186/1471-2326-12-8.

PMID:
22812631
[PubMed]
Free PMC Article
3.

An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals.

Mohammad RM, Wu J, Azmi AS, Aboukameel A, Sosin A, Wu S, Yang D, Wang S, Al-Katib AM.

Mol Cancer. 2009 Dec 3;8:115. doi: 10.1186/1476-4598-8-115.

PMID:
19958544
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.

Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C.

Clin Cancer Res. 2009 Jun 15;15(12):4038-45. doi: 10.1158/1078-0432.CCR-08-2808. Epub 2009 Jun 9.

PMID:
19509168
[PubMed - indexed for MEDLINE]
Free Article
5.

SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status.

Al-Katib AM, Sun Y, Goustin AS, Azmi AS, Chen B, Aboukameel A, Mohammad RM.

J Hematol Oncol. 2009 Feb 16;2:8. doi: 10.1186/1756-8722-2-8.

PMID:
19220884
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia.

Beck FW, Eilender DS, Dandashi MH, Siddiq F, Snell DC, Godmere MA, Al-Katib AM, Mohammad RM.

Int J Mol Med. 2004 Jul;14(1):113-9.

PMID:
15202025
[PubMed - indexed for MEDLINE]
7.
8.

The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia.

Al-Katib AM, Mensah-Osman E, Aboukameel A, Mohammad R.

Semin Oncol. 2003 Apr;30(2):313-7.

PMID:
12720160
[PubMed - indexed for MEDLINE]
9.

2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.

Mensah-Osman EJ, Al-Katib AM, Wu HY, Osman NI, Mohammad RM.

Mol Cancer Ther. 2002 Dec;1(14):1321-6.

PMID:
12516965
[PubMed - indexed for MEDLINE]
Free Article
10.
11.

Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage.

Nabha SM, Mohammad RM, Dandashi MH, Coupaye-Gerard B, Aboukameel A, Pettit GR, Al-Katib AM.

Clin Cancer Res. 2002 Aug;8(8):2735-41.

PMID:
12171907
[PubMed - indexed for MEDLINE]
Free Article
12.

Treatment-induced expression of anti-apoptotic proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line.

Wall NR, Beck FW, Al-Katib AM, Mohammad RM.

J Drug Target. 2001;9(5):329-39.

PMID:
11770703
[PubMed - indexed for MEDLINE]
13.

Mitogen-activated protein kinase is required for bryostatin 1-induced differentiation of the human acute lymphoblastic leukemia cell line Reh.

Wall NR, Mohammad RM, Al-Katib AM.

Cell Growth Differ. 2001 Dec;12(12):641-7.

PMID:
11751459
[PubMed - indexed for MEDLINE]
Free Article
14.

Phase II study of bryostatin 1 in patients with relapsed multiple myeloma.

Varterasian ML, Pemberton PA, Hulburd K, Rodriguez DH, Murgo A, Al-Katib AM.

Invest New Drugs. 2001;19(3):245-7.

PMID:
11561682
[PubMed - indexed for MEDLINE]
15.

Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy.

Nabha SM, Mohammad RM, Wall NR, Dutcher JA, Salkini BM, Pettit GR, Al-Katib AM.

Anticancer Drugs. 2001 Jan;12(1):57-63.

PMID:
11272287
[PubMed - indexed for MEDLINE]
16.
17.

Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines.

Nabha SM, Wall NR, Mohammad RM, Pettit GR, Al-Katib AM.

Anticancer Drugs. 2000 Jun;11(5):385-92.

PMID:
10912955
[PubMed - indexed for MEDLINE]
18.

Non-Hodgkin's lymphoma: an analysis of the Metropolitan Detroit SEER database.

Varterasian ML, Graff JJ, Severson RK, Weiss L, al-Katib AM, Kalemkerian GP.

Cancer Invest. 2000;18(4):303-8.

PMID:
10808365
[PubMed - indexed for MEDLINE]
19.

Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report.

Ahmad I, Al-Katib AM, Beck FW, Mohammad RM.

Clin Cancer Res. 2000 Apr;6(4):1328-32.

PMID:
10778958
[PubMed - indexed for MEDLINE]
Free Article
20.

Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Varterasian ML, Mohammad RM, Shurafa MS, Hulburd K, Pemberton PA, Rodriguez DH, Spadoni V, Eilender DS, Murgo A, Wall N, Dan M, Al-Katib AM.

Clin Cancer Res. 2000 Mar;6(3):825-8.

PMID:
10741703
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk